At OSN New York, Nicole R. Fram , MD, discusses the technological advances of the artificial iris.
Uncategorized
Uncategorized
Novel ocular insert maintains lowered IOP in patients with open-angle glaucoma or ocular hypertension
FORT LAUDERDALE, Fla. — A novel bimatoprost insert can provide IOP reduction for up to 13 consecutive months in patients with open-angle glaucoma or ocular hypertension, according to mid-term data of an open-label extension study presented here.IOP was reduced 4 mm Hg to 5 mm Hg in patients included in the study, an extension of a phase 2 clinical trial that looked at efficacy and safety of the novel bimatoprost insert, Kuldev Singh, MD, told colleagues at the American Glaucoma Society meeting, where he delivered the presentation in place of James D. Brandt, MD. In the phase 2 study, IOP in the bimatoprost insert group decreased 4 mm Hg to 6 mm Hg in months 0 to 6.
Califf: FDA Workforce Needs Strengthening
(MedPage Today) — Opioids, tobacco also to get priority from new agency boss
A Child With Strabismus
What is the cause of this boy’s ptosis and impaired eye movement? Medscape Ophthalmology
Uncategorized
Abnormal dark adaptation potential early marker of macular dysfunction in cataract surgery candidates
PHILADELPHIA — Abnormal dark adaptation is a potential marker of subclinical macular dysfunction among patients who are otherwise deemed good candidates for multifocal IOL implantation, according to a presentation here. “In early [age-related macular degeneration], Snellen visual acuity is frequently undisturbed, but problems with night vision and vision in low-light conditions are frequently reported by patients.” Marta McKeague, MD, said at the Wills Eye Alumni Conference. The symptoms are similar to cataract symptoms, making it important to differentiate between the two, she added.
Match Day 2016: Increases All Around
(MedPage Today) — Record numbers of applicants, residency slots